ID   KCAB2_RAT               Reviewed;         367 AA.
AC   P62483; P97381; Q60942; Q64284;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   02-OCT-2024, entry version 153.
DE   RecName: Full=Voltage-gated potassium channel subunit beta-2;
DE            EC=1.1.1.- {ECO:0000269|PubMed:18672894, ECO:0000269|PubMed:21209188};
DE   AltName: Full=K(+) channel subunit beta-2;
DE   AltName: Full=Kv-beta-2;
GN   Name=Kcnab2 {ECO:0000312|PDB:7SIZ}; Synonyms=Ckbeta2, Kcnb3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain cortex;
RX   PubMed=8183366; DOI=10.1038/369289a0;
RA   Rettig J., Heinemann S.H., Wunder F., Lorra C., Parcej D.N., Dolly J.O.,
RA   Pongs O.;
RT   "Inactivation properties of voltage-gated K+ channels altered by presence
RT   of beta-subunit.";
RL   Nature 369:289-294(1994).
RN   [2]
RP   INTERACTION WITH KCNA1; KCNA2; KCNA4; KCNA6 AND KCNAB1, SUBUNIT, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=9334400; DOI=10.1523/jneurosci.17-21-08246.1997;
RA   Rhodes K.J., Strassle B.W., Monaghan M.M., Bekele-Arcuri Z., Matos M.F.,
RA   Trimmer J.S.;
RT   "Association and colocalization of the Kvbeta1 and Kvbeta2 beta-subunits
RT   with Kv1 alpha-subunits in mammalian brain K+ channel complexes.";
RL   J. Neurosci. 17:8246-8258(1997).
RN   [3]
RP   FUNCTION.
RX   PubMed=9763623; DOI=10.1111/j.1469-7793.1998.325be.x;
RA   Accili E.A., Kuryshev Y.A., Wible B.A., Brown A.M.;
RT   "Separable effects of human Kvbeta1.2 N- and C-termini on inactivation and
RT   expression of human Kv1.4.";
RL   J. Physiol. (Lond.) 512:325-336(1998).
RN   [4]
RP   INTERACTION WITH SQSTM1 AND PRKCZ, AND PHOSPHORYLATION BY PRKCZ.
RX   PubMed=10477520; DOI=10.1126/science.285.5433.1565;
RA   Gong J., Xu J., Bezanilla M., van Huizen R., Derin R., Li M.;
RT   "Differential stimulation of PKC phosphorylation of potassium channels by
RT   ZIP1 and ZIP2.";
RL   Science 285:1565-1569(1999).
RN   [5]
RP   FUNCTION.
RX   PubMed=10896669; DOI=10.1074/jbc.m005010200;
RA   Manganas L.N., Trimmer J.S.;
RT   "Subunit composition determines Kv1 potassium channel surface expression.";
RL   J. Biol. Chem. 275:29685-29693(2000).
RN   [6]
RP   INTERACTION WITH KCNA1 AND KCNA2, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11086297;
RX   DOI=10.1002/1096-9861(20000101)429:1<166::aid-cne13>3.0.co;2-y;
RA   Rasband M.N., Trimmer J.S.;
RT   "Subunit composition and novel localization of K+ channels in spinal
RT   cord.";
RL   J. Comp. Neurol. 429:166-176(2001).
RN   [7]
RP   INTERACTION WITH KCNA4 AND KCND3.
RX   PubMed=12860406; DOI=10.1016/s0014-5793(03)00705-1;
RA   Wang L., Takimoto K., Levitan E.S.;
RT   "Differential association of the auxiliary subunit Kvbeta2 with Kv1.4 and
RT   Kv4.3 K+ channels.";
RL   FEBS Lett. 547:162-164(2003).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=15618540; DOI=10.1161/01.res.0000154070.06421.25;
RA   Plane F., Johnson R., Kerr P., Wiehler W., Thorneloe K., Ishii K., Chen T.,
RA   Cole W.;
RT   "Heteromultimeric Kv1 channels contribute to myogenic control of arterial
RT   diameter.";
RL   Circ. Res. 96:216-224(2005).
RN   [9]
RP   INTERACTION WITH SQSTM1; IKBKB AND TRAF6.
RX   PubMed=16079148; DOI=10.1074/jbc.c500237200;
RA   Wooten M.W., Geetha T., Seibenhener M.L., Babu J.R., Diaz-Meco M.T.,
RA   Moscat J.;
RT   "The p62 scaffold regulates nerve growth factor-induced NF-kappaB
RT   activation by influencing TRAF6 polyubiquitination.";
RL   J. Biol. Chem. 280:35625-35629(2005).
RN   [10]
RP   FUNCTION.
RX   PubMed=16770729; DOI=10.1007/s11064-006-9056-4;
RA   Fujita T., Utsunomiya I., Ren J., Matsushita Y., Kawai M., Sasaki S.,
RA   Hoshi K., Miyatake T., Taguchi K.;
RT   "Glycosylation and cell surface expression of Kv1.2 potassium channel are
RT   regulated by determinants in the pore region.";
RL   Neurochem. Res. 31:589-596(2006).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF
RP   TYR-90, AND ACTIVE SITE.
RX   PubMed=18672894; DOI=10.1021/bi800301b;
RA   Tipparaju S.M., Barski O.A., Srivastava S., Bhatnagar A.;
RT   "Catalytic mechanism and substrate specificity of the beta-subunit of the
RT   voltage-gated potassium channel.";
RL   Biochemistry 47:8840-8854(2008).
RN   [12]
RP   FUNCTION, INTERACTION WITH KCNA2, AND SUBUNIT.
RX   PubMed=18003609; DOI=10.1074/jbc.m708875200;
RA   Connors E.C., Ballif B.A., Morielli A.D.;
RT   "Homeostatic regulation of Kv1.2 potassium channel trafficking by cyclic
RT   AMP.";
RL   J. Biol. Chem. 283:3445-3453(2008).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH KCNA2 AND MAPRE1, TISSUE
RP   SPECIFICITY, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT SER-9;
RP   SER-20 AND SER-112, AND MUTAGENESIS OF SER-9; SER-20 AND SER-31.
RX   PubMed=21357749; DOI=10.1083/jcb.201007113;
RA   Vacher H., Yang J.W., Cerda O., Autillo-Touati A., Dargent B.,
RA   Trimmer J.S.;
RT   "Cdk-mediated phosphorylation of the Kvbeta2 auxiliary subunit regulates
RT   Kv1 channel axonal targeting.";
RL   J. Cell Biol. 192:813-824(2011).
RN   [14]
RP   FUNCTION, AND MUTAGENESIS OF TYR-90.
RX   PubMed=21209188; DOI=10.1523/jneurosci.2634-10.2011;
RA   Perkowski J.J., Murphy G.G.;
RT   "Deletion of the mouse homolog of KCNAB2, a gene linked to monosomy 1p36,
RT   results in associative memory impairments and amygdala hyperexcitability.";
RL   J. Neurosci. 31:46-54(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-20, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [16]
RP   SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH KCNA1 AND KCNA2, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=23318870; DOI=10.1113/jphysiol.2012.249706;
RA   Ovsepian S.V., Steuber V., Le Berre M., O'Hara L., O'Leary V.B.,
RA   Dolly J.O.;
RT   "A defined heteromeric KV1 channel stabilizes the intrinsic pacemaking and
RT   regulates the output of deep cerebellar nuclear neurons to thalamic
RT   targets.";
RL   J. Physiol. (Lond.) 591:1771-1791(2013).
RN   [17] {ECO:0007744|PDB:1QRQ}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 36-360 IN COMPLEX WITH NADP, AND
RP   SUBUNIT.
RX   PubMed=10399921; DOI=10.1016/s0092-8674(00)80805-3;
RA   Gulbis J.M., Mann S., MacKinnon R.;
RT   "Structure of a voltage-dependent K+ channel beta subunit.";
RL   Cell 97:943-952(1999).
RN   [18] {ECO:0007744|PDB:1EXB}
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 36-367 IN COMPLEX WITH NADP,
RP   INTERACTION WITH KCNA1, AND SUBUNIT.
RX   PubMed=10884227; DOI=10.1126/science.289.5476.123;
RA   Gulbis J.M., Zhou M., Mann S., MacKinnon R.;
RT   "Structure of the cytoplasmic beta subunit-T1 assembly of voltage-dependent
RT   K+ channels.";
RL   Science 289:123-127(2000).
RN   [19] {ECO:0007744|PDB:2A79}
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 36-367 IN COMPLEX WITH NADP AND
RP   KCNA2, AND SUBUNIT.
RX   PubMed=16002581; DOI=10.1126/science.1116269;
RA   Long S.B., Campbell E.B., Mackinnon R.;
RT   "Crystal structure of a mammalian voltage-dependent Shaker family K+
RT   channel.";
RL   Science 309:897-903(2005).
RN   [20] {ECO:0007744|PDB:2R9R}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 36-367 IN COMPLEX WITH NADP AND
RP   KCNA2, AND SUBUNIT.
RX   PubMed=18004376; DOI=10.1038/nature06265;
RA   Long S.B., Tao X., Campbell E.B., MacKinnon R.;
RT   "Atomic structure of a voltage-dependent K+ channel in a lipid membrane-
RT   like environment.";
RL   Nature 450:376-382(2007).
RN   [21] {ECO:0007744|PDB:3EAU, ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4}
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 36-361 IN COMPLEX WITH KCNA2;
RP   CORTISONE AND NADP, AND SUBUNIT.
RX   PubMed=18806782; DOI=10.1038/nchembio.114;
RA   Pan Y., Weng J., Kabaleeswaran V., Li H., Cao Y., Bhosle R.C., Zhou M.;
RT   "Cortisone dissociates the Shaker family K+ channels from their beta
RT   subunits.";
RL   Nat. Chem. Biol. 4:708-714(2008).
RN   [22] {ECO:0007744|PDB:3LUT}
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) IN COMPLEX WITH KCNA2 AND NADP, AND
RP   SUBUNIT.
RX   PubMed=20534430; DOI=10.1073/pnas.1000142107;
RA   Chen X., Wang Q., Ni F., Ma J.;
RT   "Structure of the full-length Shaker potassium channel Kv1.2 by normal-
RT   mode-based X-ray crystallographic refinement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11352-11357(2010).
RN   [23] {ECO:0007744|PDB:3LNM}
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 36-367 IN COMPLEX WITH KCNA2 AND
RP   NADP, AND SUBUNIT.
RX   PubMed=20360102; DOI=10.1126/science.1185954;
RA   Tao X., Lee A., Limapichat W., Dougherty D.A., MacKinnon R.;
RT   "A gating charge transfer center in voltage sensors.";
RL   Science 328:67-73(2010).
RN   [24] {ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC, ECO:0007744|PDB:4JTD}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 36-367 IN COMPLEX WITH KCNA2 AND
RP   NADP, AND SUBUNIT.
RX   PubMed=23705070; DOI=10.7554/elife.00594;
RA   Banerjee A., Lee A., Campbell E., Mackinnon R.;
RT   "Structure of a pore-blocking toxin in complex with a eukaryotic voltage-
RT   dependent K(+) channel.";
RL   Elife 2:E00594-E00594(2013).
CC   -!- FUNCTION: Regulatory subunit of the voltage-gated potassium (Kv) Shaker
CC       channels composed of pore-forming and potassium-conducting alpha
CC       subunits and of regulatory beta subunits (PubMed:10896669,
CC       PubMed:18003609, PubMed:21357749, PubMed:9763623). The beta-2/KCNAB2
CC       subunit promotes potassium channel closure via a mechanism that does
CC       not involve physical obstruction of the channel pore (PubMed:21357749).
CC       Promotes the inactivation of Kv1.4/KCNA4 and Kv1.5/KCNA5 alpha subunit-
CC       containing channels (PubMed:9763623). Displays nicotinamide adenine
CC       dinucleotide phosphate (NADPH)-dependent aldoketoreductase activity by
CC       catalyzing the NADPH-dependent reduction of a wide range of aldehyde
CC       and ketone substrates (PubMed:18672894, PubMed:21209188). Substrate
CC       specificity includes methylglyoxal, 9,10-phenanthrenequinone,
CC       prostaglandin J2, 4-nitrobenzaldehyde, 4-nitroacetophenone and 4-oxo-
CC       trans-2-nonenal (in vitro, no physiological substrate identified yet)
CC       (PubMed:18672894). The binding of oxidized and reduced nucleotide
CC       alters Kv channel gating and may contribute to dynamic fine tuning of
CC       cell excitability (PubMed:18672894). Contributes to the regulation of
CC       nerve signaling, and prevents neuronal hyperexcitability (By
CC       similarity). {ECO:0000250|UniProtKB:P62482,
CC       ECO:0000269|PubMed:10896669, ECO:0000269|PubMed:18003609,
CC       ECO:0000269|PubMed:18672894, ECO:0000269|PubMed:21209188,
CC       ECO:0000269|PubMed:21357749, ECO:0000269|PubMed:9763623}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hydroxyacetone + NADP(+) = H(+) + methylglyoxal + NADPH;
CC         Xref=Rhea:RHEA:27986, ChEBI:CHEBI:15378, ChEBI:CHEBI:17158,
CC         ChEBI:CHEBI:27957, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:18672894};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:27988;
CC         Evidence={ECO:0000305|PubMed:18672894};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E)-4-oxonon-2-en-1-ol + NADP(+) = (E)-4-oxonon-2-enal + H(+)
CC         + NADPH; Xref=Rhea:RHEA:58432, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:58972, ChEBI:CHEBI:142624;
CC         Evidence={ECO:0000269|PubMed:18672894};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:58434;
CC         Evidence={ECO:0000305|PubMed:18672894};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=209 uM for 4-nitroacetophenone {ECO:0000269|PubMed:18672894};
CC         KM=240 uM for 9,10-phenanthroquinone {ECO:0000269|PubMed:18672894};
CC         KM=283 uM for 4-nitrobenzaldehyde {ECO:0000269|PubMed:18672894};
CC         KM=12 mM for methylglyoxal {ECO:0000269|PubMed:18672894};
CC         Note=kcat is 0.092 min(-1) with 4-nitroacetophenone as substrate.
CC         kcat is 0.14 min(-1) with 9,10-phenanthroquinone as substrate. kcat
CC         is 0.16 min(-1) with 4-nitrobenzaldehyde as substrate. kcat is 0.32
CC         min(-1) with methylglyoxal as substrate. kcat is 0.028 min(-1) with
CC         4-oxonon-2-enal as substrate. {ECO:0000269|PubMed:18672894};
CC       pH dependence:
CC         Optimum pH is 7.2-7.4 for the NADPH-dependent reduction of 4-
CC         nitrobenzaldehyde. {ECO:0000269|PubMed:18672894};
CC   -!- SUBUNIT: Homotetramer (PubMed:10399921, PubMed:10884227,
CC       PubMed:16002581, PubMed:18004376, PubMed:18806782, PubMed:20360102,
CC       PubMed:20534430, PubMed:23705070). Interaction with tetrameric
CC       potassium channel alpha subunits gives rise to a heterooctamer
CC       (PubMed:10884227, PubMed:16002581, PubMed:18004376, PubMed:18806782,
CC       PubMed:20360102, PubMed:20534430, PubMed:23705070). Identified in
CC       potassium channel complexes containing KCNA1, KCNA2, KCNA4, KCNA5,
CC       KCNA6, KCNAB1, KCNAB2 and KCND3 (PubMed:10884227, PubMed:12860406,
CC       PubMed:16002581, PubMed:18003609, PubMed:18004376, PubMed:18806782,
CC       PubMed:20360102, PubMed:20534430, PubMed:21357749, PubMed:23318870,
CC       PubMed:23705070, PubMed:9334400). Interacts (in unphosphorylated form)
CC       with MAPRE1 (PubMed:21357749). Forms a ternary complex with SQSTM1 and
CC       PRKCZ (PubMed:10477520). {ECO:0000269|PubMed:10399921,
CC       ECO:0000269|PubMed:10477520, ECO:0000269|PubMed:10884227,
CC       ECO:0000269|PubMed:12860406, ECO:0000269|PubMed:16002581,
CC       ECO:0000269|PubMed:18003609, ECO:0000269|PubMed:18004376,
CC       ECO:0000269|PubMed:18806782, ECO:0000269|PubMed:20360102,
CC       ECO:0000269|PubMed:20534430, ECO:0000269|PubMed:21357749,
CC       ECO:0000269|PubMed:23318870, ECO:0000269|PubMed:23705070,
CC       ECO:0000269|PubMed:9334400}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21357749}. Membrane
CC       {ECO:0000269|PubMed:21357749, ECO:0000269|PubMed:9334400}; Peripheral
CC       membrane protein {ECO:0000305}; Cytoplasmic side {ECO:0000305}. Cell
CC       membrane {ECO:0000269|PubMed:23318870}; Peripheral membrane protein
CC       {ECO:0000305}; Cytoplasmic side {ECO:0000305}. Cell projection, axon
CC       {ECO:0000269|PubMed:21357749, ECO:0000269|PubMed:9334400}. Synapse,
CC       synaptosome {ECO:0000269|PubMed:21357749}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:21357749}. Note=Recruited to the cytoplasmic side
CC       of the cell membrane via its interaction with pore-forming potassium
CC       channel alpha subunits. Associates with microtubules when
CC       unphosphorylated (PubMed:21357749). {ECO:0000269|PubMed:21357749,
CC       ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Detected in brain (PubMed:21357749,
CC       PubMed:9334400). Detected in the middle third of the molecular layer of
CC       the dentate gyrus in hippocampus (PubMed:9334400). Detected in neurons
CC       in the deep cerebellar nucleus (PubMed:23318870). Detected in globus
CC       pallidus and pars reticulata of the substantia nigra (PubMed:9334400).
CC       Detected in cerebellum (PubMed:23318870). Detected at axon terminal
CC       plexuses of cerebellar granule cells (PubMed:9334400). Detected in the
CC       juxtaparanodal region of nodes of Ranvier in cerebellum (at protein
CC       level) (PubMed:9334400). Detected in mesenteric arteries
CC       (PubMed:15618540). {ECO:0000269|PubMed:15618540,
CC       ECO:0000269|PubMed:21357749, ECO:0000269|PubMed:23318870,
CC       ECO:0000269|PubMed:9334400}.
CC   -!- DOMAIN: In contrast to KCNAB1, the shorter N-terminal domain of KCNAB2
CC       cannot mediate closure of delayed rectifier potassium channels by
CC       physically obstructing the pore. {ECO:0000250|UniProtKB:Q13303}.
CC   -!- PTM: Phosphorylated by PRKCZ; may be regulated by incorporation in a
CC       complex composed of PRKCZ and SQSTM1. {ECO:0000269|PubMed:10477520}.
CC   -!- SIMILARITY: Belongs to the shaker potassium channel beta subunit
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X76724; CAA54142.1; -; mRNA.
DR   PIR; S45312; S45312.
DR   RefSeq; NP_059000.1; NM_017304.2.
DR   PDB; 1EXB; X-ray; 2.10 A; A=36-367.
DR   PDB; 1QRQ; X-ray; 2.80 A; A/B/C/D=36-360.
DR   PDB; 2A79; X-ray; 2.90 A; A=36-367.
DR   PDB; 2R9R; X-ray; 2.40 A; A/G=36-367.
DR   PDB; 3EAU; X-ray; 1.82 A; A=36-361.
DR   PDB; 3EB3; X-ray; 2.00 A; A=36-361.
DR   PDB; 3EB4; X-ray; 2.00 A; A=36-361.
DR   PDB; 3LNM; X-ray; 2.90 A; A/C=36-367.
DR   PDB; 3LUT; X-ray; 2.90 A; A=1-367.
DR   PDB; 4JTA; X-ray; 2.50 A; A/P=36-367.
DR   PDB; 4JTC; X-ray; 2.56 A; A/G=36-367.
DR   PDB; 4JTD; X-ray; 2.54 A; A/G=36-367.
DR   PDB; 5WIE; X-ray; 3.30 A; A/G=35-367.
DR   PDB; 6CI1; EM; 4.90 A; A/B/C/D/E/F/G/H=36-361.
DR   PDB; 6EBK; EM; 3.30 A; A/C/E/G=37-367.
DR   PDB; 6EBL; EM; 3.00 A; A/C/E/G=37-367.
DR   PDB; 7SIT; X-ray; 3.32 A; A/C=35-367.
DR   PDB; 7SIZ; X-ray; 3.10 A; A/C=35-367.
DR   PDBsum; 1EXB; -.
DR   PDBsum; 1QRQ; -.
DR   PDBsum; 2A79; -.
DR   PDBsum; 2R9R; -.
DR   PDBsum; 3EAU; -.
DR   PDBsum; 3EB3; -.
DR   PDBsum; 3EB4; -.
DR   PDBsum; 3LNM; -.
DR   PDBsum; 3LUT; -.
DR   PDBsum; 4JTA; -.
DR   PDBsum; 4JTC; -.
DR   PDBsum; 4JTD; -.
DR   PDBsum; 5WIE; -.
DR   PDBsum; 6CI1; -.
DR   PDBsum; 6EBK; -.
DR   PDBsum; 6EBL; -.
DR   PDBsum; 7SIT; -.
DR   PDBsum; 7SIZ; -.
DR   AlphaFoldDB; P62483; -.
DR   EMDB; EMD-7305; -.
DR   EMDB; EMD-9024; -.
DR   EMDB; EMD-9025; -.
DR   SMR; P62483; -.
DR   BioGRID; 248350; 7.
DR   CORUM; P62483; -.
DR   IntAct; P62483; 2.
DR   MINT; P62483; -.
DR   STRING; 10116.ENSRNOP00000073699; -.
DR   iPTMnet; P62483; -.
DR   PhosphoSitePlus; P62483; -.
DR   PaxDb; 10116-ENSRNOP00000015840; -.
DR   ABCD; P62483; 3 sequenced antibodies.
DR   GeneID; 29738; -.
DR   KEGG; rno:29738; -.
DR   UCSC; RGD:61828; rat.
DR   AGR; RGD:61828; -.
DR   CTD; 8514; -.
DR   RGD; 61828; Kcnab2.
DR   VEuPathDB; HostDB:ENSRNOG00000011550; -.
DR   eggNOG; KOG1575; Eukaryota.
DR   InParanoid; P62483; -.
DR   OrthoDB; 177088at2759; -.
DR   PhylomeDB; P62483; -.
DR   TreeFam; TF324563; -.
DR   Reactome; R-RNO-1296072; Voltage gated Potassium channels.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   EvolutionaryTrace; P62483; -.
DR   PRO; PR:P62483; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   Bgee; ENSRNOG00000011550; Expressed in frontal cortex and 20 other cell types or tissues.
DR   ExpressionAtlas; P62483; baseline and differential.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0043194; C:axon initial segment; ISO:RGD.
DR   GO; GO:0043679; C:axon terminus; ISO:RGD.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0044224; C:juxtaparanode region of axon; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:1990031; C:pinceau fiber; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISO:RGD.
DR   GO; GO:0098839; C:postsynaptic density membrane; IDA:SynGO.
DR   GO; GO:0034705; C:potassium channel complex; IDA:UniProtKB.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; ISO:RGD.
DR   GO; GO:0004033; F:aldo-keto reductase (NADPH) activity; IDA:UniProtKB.
DR   GO; GO:1990002; F:methylglyoxal reductase (NADPH) (acetol producing) activity; IEA:RHEA.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:RGD.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:RGD.
DR   GO; GO:0005249; F:voltage-gated potassium channel activity; IEA:InterPro.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISO:RGD.
DR   GO; GO:0045445; P:myoblast differentiation; IEP:RGD.
DR   GO; GO:0070995; P:NADPH oxidation; IDA:UniProtKB.
DR   GO; GO:0050905; P:neuromuscular process; ISO:RGD.
DR   GO; GO:0098900; P:regulation of action potential; IBA:GO_Central.
DR   GO; GO:1901379; P:regulation of potassium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; IMP:UniProtKB.
DR   CDD; cd19141; Aldo_ket_red_shaker; 1.
DR   Gene3D; 3.20.20.100; NADP-dependent oxidoreductase domain; 1.
DR   InterPro; IPR005983; K_chnl_volt-dep_bsu_KCNAB.
DR   InterPro; IPR005399; K_chnl_volt-dep_bsu_KCNAB-rel.
DR   InterPro; IPR005401; K_chnl_volt-dep_bsu_KCNAB2.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   InterPro; IPR036812; NADP_OxRdtase_dom_sf.
DR   NCBIfam; TIGR01293; Kv_beta; 1.
DR   PANTHER; PTHR43150; HYPERKINETIC, ISOFORM M; 1.
DR   PANTHER; PTHR43150:SF1; VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT BETA-2; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PRINTS; PR01579; KCNAB2CHANEL.
DR   PRINTS; PR01577; KCNABCHANNEL.
DR   SUPFAM; SSF51430; NAD(P)-linked oxidoreductase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Cell projection; Cytoplasm;
KW   Cytoskeleton; Ion transport; Membrane; Methylation; NADP; Oxidoreductase;
KW   Phosphoprotein; Potassium; Potassium transport; Reference proteome;
KW   Synapse; Synaptosome; Transport.
FT   CHAIN           1..367
FT                   /note="Voltage-gated potassium channel subunit beta-2"
FT                   /id="PRO_0000148748"
FT   ACT_SITE        90
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000305|PubMed:18672894"
FT   BINDING         56
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         57
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         63
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         85
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         158
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:23705070,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3LNM,
FT                   ECO:0007744|PDB:4JTA"
FT   BINDING         188
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         189
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EB3,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         214
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         243
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         244
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         245
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2R9R,
FT                   ECO:0007744|PDB:3EAU, ECO:0007744|PDB:3EB3,
FT                   ECO:0007744|PDB:3EB4, ECO:0007744|PDB:3LNM,
FT                   ECO:0007744|PDB:3LUT, ECO:0007744|PDB:4JTA,
FT                   ECO:0007744|PDB:4JTC, ECO:0007744|PDB:4JTD"
FT   BINDING         246
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         247
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:18806782, ECO:0000269|PubMed:20360102,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2R9R,
FT                   ECO:0007744|PDB:3EAU, ECO:0007744|PDB:3EB3,
FT                   ECO:0007744|PDB:3EB4, ECO:0007744|PDB:3LNM,
FT                   ECO:0007744|PDB:4JTA"
FT   BINDING         248
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTD"
FT   BINDING         254
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         262
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1QRQ,
FT                   ECO:0007744|PDB:4JTC, ECO:0007744|PDB:4JTD"
FT   BINDING         264
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         323
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:23705070,
FT                   ECO:0007744|PDB:4JTC, ECO:0007744|PDB:4JTD"
FT   BINDING         325
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         329
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         332
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:20360102,
FT                   ECO:0000269|PubMed:20534430, ECO:0000269|PubMed:23705070,
FT                   ECO:0007744|PDB:1EXB, ECO:0007744|PDB:1QRQ,
FT                   ECO:0007744|PDB:2A79, ECO:0007744|PDB:2R9R,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   BINDING         333
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:10399921,
FT                   ECO:0000269|PubMed:10884227, ECO:0000269|PubMed:16002581,
FT                   ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18806782,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000269|PubMed:23705070, ECO:0007744|PDB:1EXB,
FT                   ECO:0007744|PDB:1QRQ, ECO:0007744|PDB:2A79,
FT                   ECO:0007744|PDB:2R9R, ECO:0007744|PDB:3EAU,
FT                   ECO:0007744|PDB:3EB3, ECO:0007744|PDB:3EB4,
FT                   ECO:0007744|PDB:3LNM, ECO:0007744|PDB:3LUT,
FT                   ECO:0007744|PDB:4JTA, ECO:0007744|PDB:4JTC,
FT                   ECO:0007744|PDB:4JTD"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21357749,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13303"
FT   MOD_RES         20
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21357749,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         28
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13303"
FT   MOD_RES         28
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P62482"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13303"
FT   MOD_RES         112
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21357749"
FT   MOD_RES         124
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13303"
FT   MUTAGEN         9
FT                   /note="S->A: Impairs interaction with MAPRE1 and
FT                   association with microtubules."
FT                   /evidence="ECO:0000269|PubMed:21357749"
FT   MUTAGEN         20
FT                   /note="S->A: No effect on interaction with MAPRE1 and
FT                   association with microtubules."
FT                   /evidence="ECO:0000269|PubMed:21357749"
FT   MUTAGEN         31
FT                   /note="S->A: Impairs interaction with MAPRE1 and
FT                   association with microtubules."
FT                   /evidence="ECO:0000269|PubMed:21357749"
FT   MUTAGEN         90
FT                   /note="Y->F: Abolishes enzyme activity, but has no effect
FT                   on NADPH binding."
FT                   /evidence="ECO:0000269|PubMed:18672894,
FT                   ECO:0000269|PubMed:21209188"
FT   STRAND          38..42
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          48..55
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           59..63
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           66..78
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          83..87
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           90..93
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           94..106
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           110..112
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          114..121
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           126..128
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          129..132
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           133..147
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          152..159
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           166..178
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          181..189
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           192..204
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          212..216
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           223..236
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          239..243
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           247..252
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   TURN            253..257
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           264..266
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           271..278
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           280..299
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           303..312
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   STRAND          319..322
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           327..334
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           335..342
FT                   /evidence="ECO:0007829|PDB:3EAU"
FT   HELIX           345..355
FT                   /evidence="ECO:0007829|PDB:3EAU"
SQ   SEQUENCE   367 AA;  41021 MW;  5303FD1411B324FC CRC64;
     MYPESTTGSP ARLSLRQTGS PGMIYSTRYG SPKRQLQFYR NLGKSGLRVS CLGLGTWVTF
     GGQITDEMAE HLMTLAYDNG INLFDTAEVY AAGKAEVVLG NIIKKKGWRR SSLVITTKIF
     WGGKAETERG LSRKHIIEGL KASLERLQLE YVDVVFANRP DPNTPMEETV RAMTHVINQG
     MAMYWGTSRW SSMEIMEAYS VARQFNLIPP ICEQAEYHMF QREKVEVQLP ELFHKIGVGA
     MTWSPLACGI VSGKYDSGIP PYSRASLKGY QWLKDKILSE EGRRQQAKLK ELQAIAERLG
     CTLPQLAIAW CLRNEGVSSV LLGASNAEQL MENIGAIQVL PKLSSSIVHE IDSILGNKPY
     SKKDYRS
//
